BioCryst Pharmaceuticals BCRX AFS and Trading Securities - Unrealized Loss Position Fair Value

AFS and Trading Securities - Unrealized Loss Position Fair Value at other companies

Ionis PharmaceuticalsIONS

——

Agios PharmaceuticalsAGIO

——

Halozyme TherapeuticsHALO

——

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's afs and trading securities - unrealized loss position fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's AFS and trading securities - unrealized loss position fair value?: BioCryst Pharmaceuticals (BCRX) reported AFS and trading securities - unrealized loss position fair value of $72.27M in Q1 2026.
How has BioCryst Pharmaceuticals's AFS and trading securities - unrealized loss position fair value changed year-over-year?: BioCryst Pharmaceuticals's AFS and trading securities - unrealized loss position fair value increased by 266.2% year-over-year, from $19.74M to $72.27M.